Clinical trials in Duesseldorf – page 18

405 clinical trials in Duesseldorf, Germany across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Duesseldorf at a glance

405

clinical trials

Research sites5

Quick filters

405 trials in Duesseldorf

Open in trial search

Hormone-dependent prostate cancer+3

Not yet recruiting

BMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI

InvestigationalNo placebo

BMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:BMS-986365
Sponsor:AIO-Studien gGmbH

Contact Research Centre

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Pfizer Inc.

Contact Research Centre

Pancreatic carcinoma metastatic+1

Not yet recruiting

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Ponsegromab
Sponsor:Pfizer Inc.

Contact Research Centre

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Cholangiocarcinoma

Not yet recruiting

Study of Ivosidenib, Durvalumab, and Gemcitabine/Cisplatin for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation

Registered drugNo placebo

Study of Ivosidenib, Durvalumab, and Gemcitabine/Cisplatin for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Sickle cell disease

Not yet recruiting

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational

Germany

Participants:0–17 years · 18–64 years
Substances:(S)-2-Hydroxy-6-((4-(2-(2-Hydroxyethyl)Nicotinoyl)Morpholin-3-Yl)Methoxy)Benzaldehyde
Sponsor:Global Blood Therapeutics Inc.

Contact Research Centre

Dementia Alzheimer's type

Not yet recruiting

Study on the Safety and Effectiveness of PRI-002 for Patients with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Investigational

Study on the Safety and Effectiveness of PRI-002 for Patients with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:D-Prolyl-D-Threonyl-D-Leucyl-D-Histidyl-D-Threonyl-D-Histidyl-D-Asparaginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginine Amide Acetate
Sponsor:Prinnovation GmbH

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:GPOH gGmbH

Contact Research Centre

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Eli Lilly & Co.

Contact Research Centre

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Cytarabine
Sponsor:GPOH gGmbH

Contact Research Centre

Muscle hypertrophy

Not recruiting

Study of NT 201 compared to placebo in adults with moderate to severe platysma prominence

Investigational

Study of NT 201 compared to placebo in adults with moderate to severe platysma prominence

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Sponsor:Merz Aesthetics GmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Duesseldorf

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on colorectal cancer, breast cancer, and esophageal cancer treatments. Studies evaluate novel combination therapies and targeted treatments for various cancer types.

Metastatic Colorectal Cancer Treatment
HER2-positive Breast Cancer Therapy
Advanced Bladder Cancer Management

Research includes promising immunotherapy combinations and specialized treatments for different cancer stages.

02 Dermatological Studies

Comprehensive research on atopic dermatitis, pyoderma gangrenosum, and plaque psoriasis. Studies focus on preventive measures and innovative treatments for chronic skin conditions.

Pediatric Dermatitis Prevention
Inflammatory Skin Conditions
Advanced Psoriasis Therapeutics

Emphasis on both preventive care and treatment of severe skin manifestations.

03 Autoimmune and Inflammatory Disorders

Studies examining treatments for multiple sclerosis, uveitis, and graft-versus-host disease. Research aims to develop targeted therapies for complex autoimmune conditions.

MS Treatment Innovations
Inflammatory Eye Conditions
Transplant-Related Complications

Focus on improving patient outcomes through novel therapeutic approaches.

Back to Germany All countries